Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
$18.17
$18.16
$8.00
$21.70
$1.85B1.45361,806 shsN/A
Arvinas, Inc. stock logo
ARVN
Arvinas
$7.89
-0.1%
$7.30
$5.90
$34.11
$580.28M2.171.46 million shs826,658 shs
Forty Seven Inc stock logo
FTSV
Forty Seven
$95.51
$95.51
$5.53
$95.51
$4.60B0.41.61 million shsN/A
Insmed, Inc. stock logo
INSM
Insmed
$98.50
+0.3%
$80.87
$60.40
$106.83
$18.55B0.92.31 million shs1.76 million shs
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$23.21
0.0%
$25.17
$11.16
$27.64
$1.07B0.48915,165 shs202,316 shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
0.00%0.00%0.00%0.00%0.00%
Arvinas, Inc. stock logo
ARVN
Arvinas
0.00%+4.66%+13.54%+20.29%-66.98%
Forty Seven Inc stock logo
FTSV
Forty Seven
0.00%0.00%0.00%0.00%0.00%
Insmed, Inc. stock logo
INSM
Insmed
0.00%-1.00%+33.67%+42.38%+58.87%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
0.00%-1.17%-13.99%+0.45%+7.13%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Arvinas, Inc. stock logo
ARVN
Arvinas
3.1128 of 5 stars
4.32.00.00.00.02.51.3
Forty Seven Inc stock logo
FTSV
Forty Seven
N/AN/AN/AN/AN/AN/AN/AN/A
Insmed, Inc. stock logo
INSM
Insmed
4.162 of 5 stars
2.54.00.04.33.51.70.6
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
3.4579 of 5 stars
2.22.00.03.92.22.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
0.00
N/AN/AN/A
Arvinas, Inc. stock logo
ARVN
Arvinas
2.55
Moderate Buy$20.29157.12% Upside
Forty Seven Inc stock logo
FTSV
Forty Seven
0.00
N/AN/AN/A
Insmed, Inc. stock logo
INSM
Insmed
3.00
Buy$106.808.43% Upside
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
2.33
Hold$26.4413.96% Upside

Current Analyst Ratings Breakdown

Latest INSM, AKCA, FTSV, PCRX, and ARVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$100.00 ➝ $112.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$96.00 ➝ $110.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$99.00 ➝ $106.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$90.00 ➝ $102.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$107.00 ➝ $119.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$94.00 ➝ $109.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$90.00 ➝ $120.00
6/10/2025
Insmed, Inc. stock logo
INSM
Insmed
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
6/10/2025
Insmed, Inc. stock logo
INSM
Insmed
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy
6/10/2025
Insmed, Inc. stock logo
INSM
Insmed
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$100.00 ➝ $115.00
6/2/2025
Arvinas, Inc. stock logo
ARVN
Arvinas
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$24.00
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
$488.54M3.78$0.51 per share35.54$5.78 per share3.14
Arvinas, Inc. stock logo
ARVN
Arvinas
$263.40M2.19N/AN/A$8.17 per share0.97
Forty Seven Inc stock logo
FTSV
Forty Seven
$15.68M293.33N/AN/A$7.52 per share12.70
Insmed, Inc. stock logo
INSM
Insmed
$363.71M51.38N/AN/A$1.60 per share61.56
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$700.97M1.53$4.31 per share5.38$16.86 per share1.38
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
$40.77M$0.48N/AN/AN/A-12.34%-8.94%-8.02%N/A
Arvinas, Inc. stock logo
ARVN
Arvinas
-$198.90M-$0.66N/AN/AN/A-10.92%-7.74%-4.11%7/29/2025 (Estimated)
Forty Seven Inc stock logo
FTSV
Forty Seven
-$87.62M-$2.34N/AN/AN/AN/A-50.38%-44.35%N/A
Insmed, Inc. stock logo
INSM
Insmed
-$913.77M-$5.95N/AN/AN/A-265.93%-446.98%-52.70%8/6/2025 (Estimated)
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
-$99.56M-$2.28N/A9.03N/A-14.78%13.78%7.00%7/29/2025 (Estimated)

Latest INSM, AKCA, FTSV, PCRX, and ARVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/29/2025Q2 2025
Arvinas, Inc. stock logo
ARVN
Arvinas
-$0.87N/AN/AN/A$34.42 millionN/A
7/29/2025Q2 2025
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$0.73N/AN/AN/A$183.11 millionN/A
5/8/2025Q1 2025
Insmed, Inc. stock logo
INSM
Insmed
-$1.36-$1.42-$0.06-$1.42$91.63 million$92.82 million
5/1/2025Q1 2025
Arvinas, Inc. stock logo
ARVN
Arvinas
-$0.93$1.14+$2.07$1.14$41.87 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
N/AN/AN/AN/AN/A
Arvinas, Inc. stock logo
ARVN
Arvinas
N/AN/AN/AN/AN/A
Forty Seven Inc stock logo
FTSV
Forty Seven
N/AN/AN/AN/AN/A
Insmed, Inc. stock logo
INSM
Insmed
N/AN/AN/AN/AN/A
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
N/A
12.17
11.78
Arvinas, Inc. stock logo
ARVN
Arvinas
N/A
4.58
4.58
Forty Seven Inc stock logo
FTSV
Forty Seven
N/A
14.81
14.81
Insmed, Inc. stock logo
INSM
Insmed
11.38
5.86
5.44
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
0.48
2.41
1.99

Institutional Ownership

CompanyInstitutional Ownership
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
19.27%
Arvinas, Inc. stock logo
ARVN
Arvinas
95.19%
Forty Seven Inc stock logo
FTSV
Forty Seven
71.77%
Insmed, Inc. stock logo
INSM
Insmed
N/A
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
99.73%

Insider Ownership

CompanyInsider Ownership
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
1.50%
Arvinas, Inc. stock logo
ARVN
Arvinas
4.73%
Forty Seven Inc stock logo
FTSV
Forty Seven
37.40%
Insmed, Inc. stock logo
INSM
Insmed
3.00%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
6.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
248101.60 millionN/AOptionable
Arvinas, Inc. stock logo
ARVN
Arvinas
42072.99 million69.54 millionOptionable
Forty Seven Inc stock logo
FTSV
Forty Seven
5748.16 millionN/ANot Optionable
Insmed, Inc. stock logo
INSM
Insmed
1,271189.71 million184.02 millionOptionable
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
72046.29 million43.33 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Akcea Therapeutics stock logo

Akcea Therapeutics NASDAQ:AKCA

Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.

Arvinas stock logo

Arvinas NASDAQ:ARVN

$7.89 -0.01 (-0.11%)
Closing price 07/3/2025 02:37 PM Eastern
Extended Trading
$7.96 +0.07 (+0.87%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Forty Seven stock logo

Forty Seven NASDAQ:FTSV

Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. Forty Seven Inc. has a collaboration agreement with Genentech to include third clinical trial in non-Hodgkin's lymphoma. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.

Insmed stock logo

Insmed NASDAQ:INSM

$98.50 +0.26 (+0.26%)
Closing price 07/3/2025 03:07 PM Eastern
Extended Trading
$98.50 0.00 (0.00%)
As of 07/3/2025 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Pacira BioSciences stock logo

Pacira BioSciences NASDAQ:PCRX

$23.20 -0.01 (-0.02%)
As of 07/3/2025 01:23 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.